loading
Schlusskurs vom Vortag:
$4.51
Offen:
$4.6
24-Stunden-Volumen:
394.86K
Relative Volume:
0.38
Marktkapitalisierung:
$233.82M
Einnahmen:
$124.00K
Nettoeinkommen (Verlust:
$-49.99M
KGV:
-2.7988
EPS:
-1.69
Netto-Cashflow:
$-31.03M
1W Leistung:
-4.02%
1M Leistung:
-41.05%
6M Leistung:
-16.35%
1J Leistung:
-14.24%
1-Tages-Spanne:
Value
$4.60
$4.85
1-Wochen-Bereich:
Value
$4.41
$4.93
52-Wochen-Spanne:
Value
$3.785
$14.60

Candel Therapeutics Inc Stock (CADL) Company Profile

Name
Firmenname
Candel Therapeutics Inc
Name
Telefon
617-916-5445
Name
Adresse
117 KENDRICK STREET, NEEDHAM
Name
Mitarbeiter
38
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
CADL's Discussions on Twitter

Vergleichen Sie CADL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CADL
Candel Therapeutics Inc
4.73 233.82M 124.00K -49.99M -31.03M -1.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.37 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
582.37 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.96 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.84 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.00 26.16B 3.81B -644.79M -669.77M -6.24

Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-20 Eingeleitet Citigroup Buy
2025-02-19 Eingeleitet Canaccord Genuity Buy
2025-02-07 Eingeleitet BofA Securities Buy
2022-12-02 Eingeleitet H.C. Wainwright Buy
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-08-23 Eingeleitet Credit Suisse Outperform
2021-08-23 Eingeleitet Jefferies Buy
2021-08-23 Eingeleitet UBS Buy
Alle ansehen

Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten

pulisher
Apr 11, 2025

H.C. Wainwright maintains Buy on Candel Therapeutics stock By Investing.com - Investing.com Canada

Apr 11, 2025
pulisher
Apr 11, 2025

H.C. Wainwright maintains Buy on Candel Therapeutics stock - Investing.com Australia

Apr 11, 2025
pulisher
Apr 01, 2025

Candel Therapeutics Announces Publication of Phase 1b - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Candel Therapeutics announces publication of Phase 1b trial data on CAN-2409 - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409 - Proactive financial news

Apr 01, 2025
pulisher
Apr 01, 2025

Candel reports positive phase 1b glioma trial results By Investing.com - Investing.com UK

Apr 01, 2025
pulisher
Mar 29, 2025

Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI - Proactive financial news

Mar 29, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients - AOL.com

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Shares Are Down Today: What's Going On? - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC - Proactive financial news

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Clinical Trial for CAN-2409 Demonstrates Promising Survival Extensions for NSCLC Patients Who Failed Previous Therapies - citybiz

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Reports Positive Phase 2a Trial Results - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Trading (CADL) With Integrated Risk Controls - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Candel Therapeutics Reports Final Phase 2a Survival Data for Lung Cancer Treatment - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive To Immune Checkpoint Inhibitor (ICI) Treat - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial - Proactive Investors

Mar 26, 2025
pulisher
Mar 26, 2025

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - The Manila Times

Mar 26, 2025
pulisher
Mar 26, 2025

Breakthrough: Cancer Drug CAN-2409 Achieves 24.5-Month Survival in Advanced Lung Cancer Patients - Stock Titan

Mar 26, 2025
pulisher
Mar 26, 2025

Small cap wrap: Nano One Materials, EnWave, Summit Therapeutics... - Proactive financial news

Mar 26, 2025
pulisher
Mar 25, 2025

Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now - Zacks Investment Research

Mar 25, 2025
pulisher
Mar 21, 2025

CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan

Mar 21, 2025
pulisher
Mar 21, 2025

Candel therapeutics CEO sells $229,624 in stock By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 21, 2025

Insider Sell Alert: Paul Tak Sells 26,172 Shares of Candel Thera - GuruFocus

Mar 21, 2025
pulisher
Mar 20, 2025

Candel therapeutics chief scientific officer sells $281,672 in stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics’ chief medical officer sells $396,995 in stock By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 20, 2025

Candel therapeutics CEO sells $229,624 in stock - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics Executives Sell Shares Under Trading Plans - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics’ chief medical officer sells $396,995 in stock - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Small cap wrap: Santacruz Silver, GoviEx Uranium, Candel Therapeutics... - Proactive Investors

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics Partners With IDEA Pharma To Advance CAN-2409 Cancer Immunotherapy - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics partners with IDEA Pharma on commercialization of CAN-2409 - Proactive Investors

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics Partners With IDEA Pharma for CAN-2409 Commercialization -March 20, 2025 at 08:29 am EDT - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics and IDEA Pharma Announce Strategic - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

Breakthrough Prostate Cancer Drug Shows 30% Better Results as Candel Secures Key Partnership - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

Candel therapeutics CFO Charles Schoch sells $44,169 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Candel therapeutics CTO sells $275,947 worth of common stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Candel therapeutics CTO sells $275,947 worth of common stock - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Candel therapeutics CFO Charles Schoch sells $44,169 in stock - Investing.com

Mar 19, 2025
pulisher
Mar 18, 2025

Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors

Mar 18, 2025
pulisher
Mar 18, 2025

Candel Therapeutics appoints cancer immunology expert to research advisory board - Proactive financial news

Mar 18, 2025
pulisher
Mar 18, 2025

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Candel Therapeutics Appoints Renowned Pancreatic Cancer - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Top Pancreatic Cancer Expert Joins Candel Therapeutics Following Promising Trial Results - StockTitan

Mar 18, 2025

Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Candel Therapeutics Inc-Aktie (CADL) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Nichols William Garrett
Chief Medical Officer
Mar 18 '25
Sale
8.76
45,316
396,995
52,493
Barone Francesca
Chief Scientific Officer
Mar 18 '25
Option Exercise
1.55
18,000
27,900
128,673
Barone Francesca
Chief Scientific Officer
Mar 18 '25
Sale
8.76
32,146
281,673
96,527
Tak Paul Peter
Chief Executive Officer
Mar 18 '25
Sale
8.77
25,772
226,023
226,140
Tak Paul Peter
Chief Executive Officer
Mar 19 '25
Sale
9.00
400
3,601
225,740
Tyagarajan Seshu
Chief Technology Officer
Mar 17 '25
Sale
8.82
31,278
275,947
85,512
Schoch Charles
See Remarks
Mar 17 '25
Sale
8.83
5,000
44,169
38,038
$19.80
price down icon 1.75%
$70.30
price up icon 2.22%
$32.51
price up icon 0.87%
$26.24
price up icon 1.84%
$102.53
price down icon 0.01%
biotechnology ONC
$248.35
price up icon 8.46%
Kapitalisierung:     |  Volumen (24h):